SYS-CON MEDIA Authors: Raja Patel, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Nordic Nanovector: Listing on NOTC

Nordic Nanovector (the “Company”) announces that its shares will be registered in the Norwegian OTC system (NOTC) from today, 7 July 2014, under the symbol ‘NANO’. The share capital increase in connection with the recent NOK 250 million private placement at a subscription price of NOK 25 has been registered in the Norwegian Register of Business Enterprises and the number of shares currently outstanding is 22,821,375.

As resolved by the Company’s general meeting on 27 June 2014, the Company will effect a subsequent repair issue of up to 2,000,000 new shares at a subscription price of NOK 25 per share in August/September 2014. Further details will be announced in due course.

In addition, as described in the Company’s press release dated 27 September 2013, 1,666,666 shares will no later than 15 October 2014 be issued to HealthCap VI L.P. at a subscription price of NOK 15 in connection with the private placement completed in September 2013.

About Nordic Nanovector

AS Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin

Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).

This information was brought to you by Cision http://news.cision.com

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.